Wang L, Wang FS, Gershwin ME (2015) Human autoimmune diseases: a comprehensive update. J Intern Med 278(4):369–395

Article  PubMed  CAS  Google Scholar 

Schett G, Mackensen A, Mougiakakos D (2023) CAR T-cell therapy in autoimmune diseases. Lancet 402(10416):2034–2044

Article  PubMed  CAS  Google Scholar 

Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR et al (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350(25):2572–2581

Article  PubMed  CAS  Google Scholar 

Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC et al (2010) Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 62(1):222–233

Article  PubMed  PubMed Central  CAS  Google Scholar 

Treppo E, Binutti M, Agarinis R, De Vita S, Quartuccio L (2021) Rituximab induction and maintenance in ANCA-associated vasculitis: state of the art and future perspectives. J Clin Med 10:17

Article  Google Scholar 

Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC et al (2013) Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 65(2):314–324

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ebata S, Yoshizaki A, Oba K, Kashiwabara K, Ueda K, Uemura Y et al (2021) Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial. Lancet Rheumatol 3(7):e489–e497

Article  PubMed  CAS  Google Scholar 

Terrier B, Amoura Z, Ravaud P, Hachulla E, Jouenne R, Combe B et al (2010) Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum 62(8):2458–2466

Article  PubMed  CAS  Google Scholar 

Weiner GJ (2010) Rituximab: mechanism of action. Semin Hematol 47(2):115–123

Article  PubMed  PubMed Central  CAS  Google Scholar 

Forsthuber TG, Cimbora DM, Ratchford JN, Katz E, Stüve O (2018) B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets. Ther Adv Neurol Disord 11:1756286418761697

Article  PubMed  PubMed Central  CAS  Google Scholar 

Anolik JH, Barnard J, Owen T, Zheng B, Kemshetti S, Looney RJ, Sanz I (2007) Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum 56(9):3044–3056

Article  PubMed  CAS  Google Scholar 

June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC (2018) CAR T cell immunotherapy for human cancer. Science 359(6382):1361–1365

Article  PubMed  CAS  Google Scholar 

Al Hadidi S, Heslop HE, Brenner MK, Suzuki M (2024) Bispecific antibodies and autologous chimeric antigen receptor T cell therapies for treatment of hematological malignancies. Mol Ther

Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Science translational medicine. 2011;3(95):95ra73–95ra73.

Porter DL, Levine BL, Kalos M, Bagg A, June CH (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365(8):725–733

Article  PubMed  PubMed Central  CAS  Google Scholar 

Bergmann C, Müller F, Distler JHW, Györfi AH, Völkl S, Aigner M et al (2023) Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells. Ann Rheum Dis 82(8):1117–1120

Article  PubMed  Google Scholar 

Pecher AC, Hensen L, Klein R, Schairer R, Lutz K, Atar D et al (2023) CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome. JAMA 329(24):2154–2162

Article  PubMed  PubMed Central  CAS  Google Scholar 

Mougiakakos D, Krönke G, Völkl S, Kretschmann S, Aigner M, Kharboutli S et al (2021) CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N Engl J Med 385(6):567–569

Article  PubMed  Google Scholar 

Müller F, Boeltz S, Knitza J, Aigner M, Völkl S, Kharboutli S et al (2023) CD19-targeted CAR T cells in refractory antisynthetase syndrome. Lancet 401(10379):815–818

Article  PubMed  Google Scholar 

Müller F, Taubmann J, Bucci L, Wilhelm A, Bergmann C, Völkl S et al (2024) CD19 CAR T-cell therapy in autoimmune disease: a case series with follow-up. N Engl J Med 390(8):687–700

Article  PubMed  Google Scholar 

Kansal R, Richardson N, Neeli I, Khawaja S, Chamberlain D, Ghani M et al (2019) Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. Sci Transl Med 11:482

Article  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71

Article  PubMed  PubMed Central  Google Scholar 

Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31(11):1409–1417

Article  PubMed  Google Scholar 

Gladman DD, Ibañez D, Urowitz MB (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29(2):288–291

PubMed  Google Scholar 

van Vollenhoven RF, Bertsias G, Doria A, Isenberg D, Morand E, Petri MA et al (2021) 2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Sci Med 8:1

Google Scholar 

Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae S-C et al (2024) EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 83(1):15–29

Article  PubMed  CAS  Google Scholar 

Aggarwal R, Rider LG, Ruperto N, Bayat N, Erman B, Feldman BM et al (2017) 2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Ann Rheum Dis 76(5):792–801

Article  PubMed  Google Scholar 

Ross L, Stevens W, Wilson M, Huq M, Strickland G, Walker J et al (2020) Performance of the 2017 EUSTAR activity index in an scleroderma cohort. Clin Rheumatol 39(12):3701–3705

Article  PubMed  Google Scholar 

Steen VD, Medsger TA Jr (2001) Improvement in skin thickening in systemic sclerosis associated with improved survival. Arthritis Rheum 44(12):2828–2835

Article  PubMed  CAS  Google Scholar 

Munn Z, Barker TH, Moola S, Tufanaru C, Stern C, McArthur A et al (2020) Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synth 18(10):2127–2133

PubMed  Google Scholar 

Zhang W, Feng J, Cinquina A, Wang Q, Xu H, Zhang Q et al (2021) Treatment of Systemic Lupus Erythematosus using BCMA-CD19 Compound CAR. Stem Cell Rev Rep 17(6):2120–2123

Article  PubMed  PubMed Central  Google Scholar 

Li M, Zhang Y, Jiang N, Ning C, Wang Q, Xu D et al (2024) Anti–CD19 CAR T cells in refractory immune thrombocytopenia of SLE. N Engl J Med 391(4):376–378

Article  PubMed  Google Scholar 

Yuan Y, He S, Zhang W, Zhang H, Destefano V, Wada M et al (2023) POS1134 novel approach to treat systemic lupus erythematosus, by targeting the “root cause”, B cells and plasma cells, using BCMA-CD19 compound car. Ann Rheum Dis 82(Suppl 1):895

Google Scholar 

Feng J, Hu Y, Chang AH, Huang H (2023) CD19/BCMA CAR-T cell therapy for refractory systemic lupus erythematosus: safety and preliminary efficacy data from a phase I clinical study. Blood 142:4835

Article  Google Scholar 

Wang W, He S, Zhang W, Zhang H, DeStefano VM, Wada M et al (2024) BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial. Ann Rheum Dis 83(10):1304–1314